Literature DB >> 3161165

Local cerebral glucose utilization in symptomatic and presymptomatic Huntington's disease.

D E Kuhl, C H Markham, E J Metter, W H Riege, M E Phelps, J C Mazziotta.   

Abstract

Patterns of local cerebral glucose utilization were measured with positron emission CT using the 18F-fluorodeoxyglucose method in 13 patients with HD, 15 subjects at risk for HD, and control subjects. These data were compared with CT measures of cerebral atrophy, age, and duration and severity of symptoms. The results indicate that in HD there is a characteristic decrease in glucose utilization in the caudate and putamen and that this local hypometabolism appears early and precedes bulk tissue loss. In contrast to demented patients with Alzheimer's disease or Parkinson's disease, in these HD patients glucose utilization typically was normal throughout the rest of the brain, regardless of the severity of symptoms and despite apparent shrinkage of brain tissue. Our results indicate that the caudate is hypometabolic in some asymptomatic persons who are carriers of the autosomal-dominant gene for HD.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3161165

Source DB:  PubMed          Journal:  Res Publ Assoc Res Nerv Ment Dis        ISSN: 0091-7443


  14 in total

1.  Meclizine is neuroprotective in models of Huntington's disease.

Authors:  Vishal M Gohil; Nicolas Offner; James A Walker; Sunil A Sheth; Elisa Fossale; James F Gusella; Marcy E MacDonald; Christian Neri; Vamsi K Mootha
Journal:  Hum Mol Genet       Date:  2010-10-25       Impact factor: 6.150

Review 2.  The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's disease.

Authors:  Aris A Polyzos; Cynthia T McMurray
Journal:  Mech Ageing Dev       Date:  2016-09-12       Impact factor: 5.432

3.  Oxidative metabolism in YAC128 mouse model of Huntington's disease.

Authors:  James Hamilton; Jessica J Pellman; Tatiana Brustovetsky; Robert A Harris; Nickolay Brustovetsky
Journal:  Hum Mol Genet       Date:  2015-06-03       Impact factor: 6.150

4.  Abnormalities in the tricarboxylic Acid cycle in Huntington disease and in a Huntington disease mouse model.

Authors:  Nima N Naseri; Hui Xu; Joseph Bonica; Jean Paul G Vonsattel; Etty P Cortes; Larry C Park; Jamshid Arjomand; Gary E Gibson
Journal:  J Neuropathol Exp Neurol       Date:  2015-06       Impact factor: 3.685

5.  Striatal metabolism and psychomotor speed as predictors of motor onset in Huntington's disease.

Authors:  Meike Herben-Dekker; Joost C H van Oostrom; Raymund A C Roos; Caroline K Jurgens; Marie-Noëlle W Witjes-Ané; Hubertus P H Kremer; Klaus L Leenders; Jacoba M Spikman
Journal:  J Neurol       Date:  2014-04-30       Impact factor: 4.849

6.  Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease.

Authors:  Jinho Kim; Daniel J Amante; Jennifer P Moody; Christina K Edgerly; Olivia L Bordiuk; Karen Smith; Samantha A Matson; Wayne R Matson; Clemens R Scherzer; H Diana Rosas; Steven M Hersch; Robert J Ferrante
Journal:  Biochim Biophys Acta       Date:  2010-05-09

Review 7.  Functional imaging in Huntington's disease.

Authors:  Jane S Paulsen
Journal:  Exp Neurol       Date:  2009-01-03       Impact factor: 5.330

8.  Regional vulnerability in Huntington's disease: fMRI-guided molecular analysis in patients and a mouse model of disease.

Authors:  Nicole M Lewandowski; Yvette Bordelon; Adam M Brickman; Sergio Angulo; Usman Khan; Jordan Muraskin; Erica Y Griffith; Paula Wasserman; Liliana Menalled; Jean Paul Vonsattel; Karen Marder; Scott A Small; Herman Moreno
Journal:  Neurobiol Dis       Date:  2012-12-04       Impact factor: 5.996

Review 9.  The energetics of Huntington's disease.

Authors:  Susan E Browne; M Flint Beal
Journal:  Neurochem Res       Date:  2004-03       Impact factor: 3.996

10.  Imaging of cerebral blood flow markers in Huntington's disease using single photon emission computed tomography.

Authors:  I C Reid; J A Besson; P V Best; P F Sharp; H G Gemmell; F W Smith
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-10       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.